Warning: Creating default object from empty value in /home/nen/public_html/wp-content/themes/salient/nectar/redux-framework/ReduxCore/inc/class.redux_filesystem.php on line 29
The Natural History of Subclinical Hyperthyroidism in Graves’ Disease: The Rule of Thirds – North East Endocrine Network

The Natural History of Subclinical Hyperthyroidism in Graves’ Disease: The Rule of Thirds

By February 14, 2017 No Comments

Sviatlana Zhyzhneuskaya, Caroline Addison, Vasileios Tsatlidis, Jolanta U. Weaver, Salman Razvi.

Thyroid. Jun 2016, 26(6): 765-769

 

BACKGROUND:

There is little information regarding the natural history of subclinical hyperthyroidism (SH) due to Graves’ disease (GD).

METHODS:

A prospective analysis was conducted of patients with SH due to GD between 2007 and 2013 with at least 12 months of follow-up. SH was diagnosed if serum thyrotropin (TSH) was below the laboratory reference range (0.4-4.0 mIU/L) and when thyroid hormones were normal. GD was confirmed by either a raised TSH receptor antibody (TRAb) level or uniform uptake on Technetium scan.

RESULTS:

Forty-four patients (89% female, 16% current smokers, and 5% with active Graves’ orbitopathy) were diagnosed with SH due to GD. Over the follow-up period (median 32 months), approximately one third (34%) of the cohort progressed to overt hyperthyroidism, one third (34%) normalized their thyroid function, slightly less than one third (30%) remained in the SH state, while one person became hypothyroid. Multivariate regression analysis showed that older age and positive antithyroid peroxidase (TPO) antibody status had a positive association with risk of progression to overt hyperthyroidism, with hazard ratios of 1.06 ([confidence interval (CI) 1.02-1.10], p < 0.01) per year and 10.15 ([CI 1.83-56.23], p < 0.01), respectively, independent of other risk factors including, smoking, TRAb levels at diagnosis, and sex.

CONCLUSIONS:

A third each of patients with SH due to GD progress, normalize, or remain in the SH state. Older people and those with positive anti-TPO antibodies have a higher risk of progression of the disease. These novel data need to be verified and confirmed in larger cohorts and over longer periods of follow-up.